Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 188

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions

Dominiak, Agnieszka, Chełstowska, Beata, Olejarz, Wioletta, Nowicka, Grażyna · 2020 · Cancers

Abstract

The tumor microenvironment (TME) is a complex system composed of multiple cells, such as non-cancerous fibroblasts, adipocytes, immune and vascular cells, as well as signal molecules and mediators. Tumor cells recruit and reprogram other cells to produce factors that maintain tumor growth. Communication between cancerous and surrounding cells is a two-way process and engages a diverse range of mechanisms that, in consequence, can lead to rapid proliferation, metastasis, and drug resistance, or can serve as a tumors-suppressor, e.g., through tumor–immune cell interaction. Cross-talk within the cancer microenvironment can be direct by cell-to-cell contact via adhesion molecules, electrical coupling, and passage through gap junctions, or indirect through classical paracrine signaling by cytokines, growth factors, and extracellular vesicles. Therapeutic approaches for modulation of cell-cell communication may be a promising strategy to combat tumors. In particular, integrative approaches targeting tumor communication in combination with conventional chemotherapy seem reasonable. Currently, special attention is paid to suppressing the formation of open-ended channels as well as blocking exosome production or ablating their cargos. However, many aspects of cell-to-cell communication have yet to be clarified, and, in particular, more work is needed in regard to mechanisms of bidirectional signal transfer. Finally, it seems that some interactions in TEM can be not only cancer-specific, but also patient-specific, and their recognition would help to predict patient response to therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers12051232

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 174

  1. Bode, 2009, Cancer prevention research—Then and now, Nat. Rev. Cancer, 9, 508, 10.1038/nrc2646 · DOI · Paper page
  2. Helsper, 2017, Time to diagnosis and treatment for cancer patients in the Netherlands: Room for improvement?, Eur. J. Cancer, 87, 113, 10.1016/j.ejca.2017.10.003 · doi:10.1016/j.ejca.2017.10.003
  3. Schirrmacher, 2019, From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review), Int. J. Oncol., 54, 407, 10.3892/ijo.2018.4661 · DOI · Paper page
  4. Bergfeld, 2010, Bone marrow-derived mesenchymal stem cells and the tumor microenvironment, Cancer Metastasis Rev., 29, 249, 10.1007/s10555-010-9222-7 · DOI · Paper page
  5. Walker, C., Mojares, E., and Del Rio Hernandez, A. (2018). Role of Extracellular Matrix in Development and Cancer Progression. Int. J. Mol. Sci., 19. · DOI · Paper page
  6. Taube, 2018, Implications of the tumor immune microenvironment for staging and therapeutics, Modem Pathol., 31, 214, 10.1038/modpathol.2017.156 · DOI · Paper page
  7. Pasquier, 2013, Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance, J. Transl. Med., 11, 94, 10.1186/1479-5876-11-94 · DOI · Paper page
  8. Polak, 2015, B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment, Blood, 126, 2404, 10.1182/blood-2015-03-634238 · DOI · Paper page
  9. Petrova, 2018, The hypoxic tumour microenvironment, Oncogenesis, 7, 10, 10.1038/s41389-017-0011-9 · DOI · Paper page
  10. Albrengues, 2015, Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts, Nat. Commun., 6, 10204, 10.1038/ncomms10204 · DOI · Paper page
  11. Albrengues, 2014, LIF mediates proinvasive activation of stromal fibroblasts in cancer, Cell Rep., 7, 1664, 10.1016/j.celrep.2014.04.036 · DOI · Paper page
  12. Scharenberg, 2014, TGF-β-induced differentiation into myofibroblasts involves specific regulation of two MKL1 isoforms, J. Cell Sci., 127, 1079
  13. Aasen, 2019, Connexins in cancer: Bridging the gap to the clinic, Oncogene, 38, 4429, 10.1038/s41388-019-0741-6 · DOI · Paper page
  14. Qu, 2002, Function of the voltage gate of gap junction channels: Selective exclusion of molecules, Proc. Natl. Acad. Sci. USA, 99, 697, 10.1073/pnas.022324499 · DOI
  15. Beckmann, A., Hainz, N., Tschernig, T., and Meier, C. (2019). Facets of Communication: Gap Junction Ultrastructure and Function in Cancer Stem Cells and Tumor Cells. Cancers (Basel), 11. · DOI
  16. Aasen, 2016, Gap junctions and cancer: Communicating for 50 years, Nat. Rev. Cancer, 16, 775, 10.1038/nrc.2016.105 · DOI · Paper page
  17. Loewenstein, 1966, Intercellular communication and the control of tissue growth: Lack of communication between cancer cells, Nature, 209, 1248, 10.1038/2091248a0 · DOI · Paper page
  18. Babica, 2016, Chemopreventive Agents Attenuate Rapid Inhibition of Gap Junctional Intercellular Communication Induced by Environmental Toxicants, Nutr. Cancer, 68, 827, 10.1080/01635581.2016.1180409 · DOI
  19. Xu, 2016, Reduced Connexin 43 expression is associated with tumor malignant behaviors and biochemical recurrence-free survival of prostate cancer, Oncotarget, 7, 67476, 10.18632/oncotarget.11231 · doi:10.18632/oncotarget.11231
  20. Yeh, 2017, Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration, Oncotarget, 8, 109358, 10.18632/oncotarget.22678 · DOI
  21. Arshad, 2018, Inhibition of Cx43 attenuates ERK1/2 activation, enhances the expression of Cav1 and suppresses cell proliferation, Int. J. Mol. Med., 42, 2811
  22. Sinyuk, 2018, Cancer Connectors: Connexins, Gap Junctions, and Communication, Front. Oncol., 8, 646, 10.3389/fonc.2018.00646 · DOI
  23. Kar, 2012, Biological role of connexin intercellular channels and hemichannels, Arch. Biochem. Biophys., 524, 2, 10.1016/j.abb.2012.03.008 · DOI · Paper page
  24. Sin, 2012, Opposing roles of connexin43 in glioma progression, Biochim. Biophys. Acta, 1818, 2058, 10.1016/j.bbamem.2011.10.022 · DOI
  25. Arora, S., Heyza, J.R., Chalfin, E.C., Ruch, R.J., and Patrick, S.M. (2018). Gap Junction Intercellular Communication Positively Regulates Cisplatin Toxicity by Inducing DNA Damage through Bystander Signaling. Cancers (Basel), 10. · DOI
  26. Mattes, 2018, Emerging role of contact-mediated cell communication in tissue development and diseases, Histochem. Cell Biol., 150, 431, 10.1007/s00418-018-1732-3 · DOI
  27. Bosenberg, 1993, Juxtacrine cell signaling molecules, Curr. Opin. Cell Biol., 5, 832, 10.1016/0955-0674(93)90032-L · DOI
  28. Cuatrecasas, 1974, Membrane receptors, Annu. Rev. Biochem., 43, 169, 10.1146/annurev.bi.43.070174.001125 · DOI · Paper page
  29. Sever, R., and Brugge, J.S. (2015). Signal transduction in cancer. Cold Spring Harb. Perspect. Med., 5. · DOI · Paper page
  30. Ikenouchi, 2003, Regulation of tight junctions during the epithelium-mesenchyme transition: Direct repression of the gene expression of claudins/occludin by Snail, J. Cell Sci., 116, 1959, 10.1242/jcs.00389 · DOI · Paper page
  31. Martin, 2014, The role of tight junctions in cancer metastasis, Semin. Cell Dev. Biol., 36, 224, 10.1016/j.semcdb.2014.09.008 · DOI
  32. Ren, 1990, Ultrastructural differences in junctional intercellular communication between highly and weakly metastatic clones derived from rat mammary carcinoma, Cancer Res., 50, 358
  33. Takeichi, 2014, Dynamic contacts: Rearranging adherens junctions to drive epithelial remodelling, Nat. Rev. Mol. Cell Biol., 15, 397, 10.1038/nrm3802 · DOI · Paper page
  34. Ling, 2011, Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer, Int. J. Mol. Med., 27, 625, 10.3892/ijmm.2011.640 · DOI
  35. Mayer, 1993, E-cadherin expression in primary and metastatic gastric cancer: Down-regulation correlates with cellular dedifferentiation and glandular disintegration, Cancer Res., 53, 1690
  36. Zhai, 2008, Reduced expression of E-cadherin/catenin complex in hepatocellular carcinomas, World J. Gastroenterol., 14, 5665, 10.3748/wjg.14.5665 · doi:10.3748/wjg.14.5665
  37. Shiina, 2005, Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer, Cancer Res., 65, 2130, 10.1158/0008-5472.CAN-04-3398 · DOI
  38. Dusek, 2011, Desmosomes: New perpetrators in tumour suppression, Nat. Rev. Cancer, 11, 317, 10.1038/nrc3051 · DOI · Paper page
  39. Roehlecke, C., and Schmidt, M.H.H. (2020). Tunneling Nanotubes and Tumor Microtubes in Cancer. Cancers (Basel), 12. · DOI
  40. Drab, M., Stopar, D., Kralj-Iglic, V., and Iglic, A. (2019). Inception Mechanisms of Tunneling Nanotubes. Cells, 8. · DOI
  41. Morel, 2017, Role of connexin 43 in different forms of intercellular communication—Gap junctions, extracellular vesicles and tunnelling nanotubes, J. Cell Sci., 130, 3619, 10.1242/jcs.200667 · DOI · Paper page
  42. Desir, S., Wong, P., Turbyville, T., Shetty, M., Clark, C., Zhai, E., Romin, Y., Manova-Todorova, K., and Starr, T.K. (2019). Intercellular Transfer of Oncogenic KRAS via Tunneling Nanotubes Introduces Intracellular Mutational Heterogeneity in Colon Cancer Cells. Cancers (Basel), 11. · DOI
  43. Berruti, 2018, RalGPS2 is involved in tunneling nanotubes formation in 5637 bladder cancer cells, Exp. Cell Res., 362, 349, 10.1016/j.yexcr.2017.11.036 · DOI
  44. Asencio-Barria, C., Defamie, N., Saez, J.C., Mesnil, M., and Godoy, A.S. (2019). Direct Intercellular Communications and Cancer: A Snapshot of the Biological Roles of Connexins in Prostate Cancer. Cancers (Basel), 11. · DOI
  45. Pasquier, 2012, Different modalities of intercellular membrane exchanges mediate cell-to-cell p-glycoprotein transfers in MCF-7 breast cancer cells, J. Biol. Chem., 287, 7374, 10.1074/jbc.M111.312157 · DOI
  46. Thayanithy, 2014, Tumor-stromal cross talk: Direct cell-to-cell transfer of oncogenic microRNAs via tunneling nanotubes, Transl. Res., 164, 359, 10.1016/j.trsl.2014.05.011 · DOI · Paper page
  47. Nawaz, 2017, Extracellular Vesicles, Tunneling Nanotubes, and Cellular Interplay: Synergies and Missing Links, Front. Mol. Biosci., 4, 50, 10.3389/fmolb.2017.00050 · DOI
  48. Murray, 2019, Concise Review: Intercellular Communication Via Organelle Transfer in the Biology and Therapeutic Applications of Stem Cells, Stem Cells, 37, 14, 10.1002/stem.2922 · DOI
  49. Wang, 2011, Tunneling-nanotube development in astrocytes depends on p53 activation, Cell Death Differ., 18, 732, 10.1038/cdd.2010.147 · DOI · Paper page
  50. Babenko, 2015, Improving the Post-Stroke Therapeutic Potency of Mesenchymal Multipotent Stromal Cells by Cocultivation with Cortical Neurons: The Role of Crosstalk Between Cells, Stem Cells Transl. Med., 4, 1011, 10.5966/sctm.2015-0010 · DOI
  51. Osswald, 2015, Brain tumour cells interconnect to a functional and resistant network, Nature, 528, 93, 10.1038/nature16071 · DOI · Paper page
  52. Osswald, 2016, A malignant cellular network in gliomas: Potential clinical implications, Neuro Oncol., 18, 479, 10.1093/neuonc/now014 · DOI
  53. Abounit, 2015, Identification and Characterization of Tunneling Nanotubes for Intercellular Trafficking, Curr. Protoc. Cell Biol., 67, 12.10.11, 10.1002/0471143030.cb1210s67 · DOI
  54. Okafo, 2017, Tunneling nanotubes (TNT) mediate long-range gap junctional communication: Implications for HIV cell to cell spread, Sci. Rep., 7, 16660, 10.1038/s41598-017-16600-1 · DOI
  55. Liu, 2019, Exosomes as critical mediators of cell-to-cell communication in cancer pathogenesis and their potential clinical application, Transl. Cancer Res., 8, 298, 10.21037/tcr.2019.01.03 · DOI
  56. Kanada, 2016, Signaling by Extracellular Vesicles Advances Cancer Hallmarks, Trends Cancer, 2, 84, 10.1016/j.trecan.2015.12.005 · DOI
  57. Lotvall, 2014, Minimal experimental requirements for definition of extracellular vesicles and their functions: A position statement from the International Society for Extracellular Vesicles, J. Extracell. Vesicles, 3, 26913, 10.3402/jev.v3.26913 · DOI · Paper page
  58. Sadallah, 2011, Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells, J. Immunol., 186, 6543, 10.4049/jimmunol.1002788 · DOI · Paper page
  59. Savina, 2005, Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner, Traffic, 6, 131, 10.1111/j.1600-0854.2004.00257.x · DOI · Paper page
  60. Oves, M., Qari, H., Felemban, N., Aslam, A., Khan, A.A., Rehan, M., Tabrez, S., Ahmed, F., Haque, A., and Khan, I. (2018). Exosomes: A Paradigm in Drug Development against Cancer and Infectious Diseases. J. Nanomater., 2018. · DOI
  61. Bujanda, 2016, Glypican-1 in exosomes as biomarker for early detection of pancreatic cancer, Ann. Transl. Med., 4, 64
  62. Melo, 2014, Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis, Cancer Cell, 26, 707, 10.1016/j.ccell.2014.09.005 · DOI · Paper page
  63. Lv, 2012, Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro, J. Biol. Chem., 287, 15874, 10.1074/jbc.M112.340588 · DOI · Paper page
  64. Cheng, 2017, A comprehensive overview of exosomes in ovarian cancer: Emerging biomarkers and therapeutic strategies, J. Ovarian Res., 10, 73, 10.1186/s13048-017-0368-6 · DOI
  65. Blancas, 2018, The role of exosomes on colorectal cancer: A review, J. Gastroenterol. Hepatol., 33, 792, 10.1111/jgh.14049 · DOI
  66. Lowry, 2015, The Role of Exosomes in Breast Cancer, Clin. Chem., 61, 1457, 10.1373/clinchem.2015.240028 · DOI
  67. Tucci, 2018, Exosomes in melanoma: A role in tumor progression, metastasis and impaired immune system activity, Oncotarget, 9, 20826, 10.18632/oncotarget.24846 · DOI
  68. Pan, 2017, Exosomes in diagnosis and therapy of prostate cancer, Oncotarget, 8, 97693, 10.18632/oncotarget.18532 · DOI
  69. Corcoran, C., Rani, S., O’Brien, K., O’Neill, A., Prencipe, M., Sheikh, R., Webb, G., McDermott, R., Watson, W., and Crown, J. (2012). Docetaxel-resistance in prostate cancer: Evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS ONE, 7. · DOI · Paper page
  70. Kong, 2015, Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells, Int. J. Cancer, 137, 1610, 10.1002/ijc.29542 · DOI
  71. Xiao, X., Yu, S., Li, S., Wu, J., Ma, R., Cao, H., Zhu, Y., and Feng, J. (2014). Exosomes: Decreased sensitivity of lung cancer A549 cells to cisplatin. PLoS ONE, 9. · DOI · Paper page
  72. Takahashi, 2014, Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer, FEBS Open Bio, 4, 458, 10.1016/j.fob.2014.04.007 · DOI · Paper page
  73. Li, 2005, Nanovesicular vaccines: Exosomes, Arch. Immunol. Ther. Exp. (Warsz), 53, 329
  74. Peinado, 2012, Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET, Nat. Med., 18, 883, 10.1038/nm.2753 · DOI · Paper page
  75. Whiteside, 2018, Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment, Semin. Immunol., 35, 69, 10.1016/j.smim.2017.12.003 · DOI · Paper page
  76. Peinado, 2017, Pre-metastatic niches: Organ-specific homes for metastases, Nat. Rev. Cancer, 17, 302, 10.1038/nrc.2017.6 · DOI · Paper page
  77. Liu, 2015, The exosomes in tumor immunity, Oncoimmunology, 4, e1027472, 10.1080/2162402X.2015.1027472 · DOI · Paper page
  78. Sethi, 2012, Multifaceted link between cancer and inflammation, Biosci. Rep., 32, 1, 10.1042/BSR20100136 · DOI · Paper page
  79. Amedei, 2013, The use of cytokines and chemokines in the cancer immunotherapy, Recent Pat. Anticancer Drug Discov., 8, 126, 10.2174/1574892811308020002 · DOI
  80. Li, 2009, Paradoxical roles of IL-4 in tumor immunity, Cell. Mol. Immunol., 6, 415, 10.1038/cmi.2009.53 · DOI
  81. Middleton, 2014, Interleukin-6: An angiogenic target in solid tumours, Crit. Rev. Oncol. Hematol., 89, 129, 10.1016/j.critrevonc.2013.08.004 · DOI
  82. 2006, The multifaceted roles of chemokines in malignancy, Cancer Metastasis Rev., 25, 357, 10.1007/s10555-006-9003-5 · DOI · Paper page
  83. Mannino, 2015, The paradoxical role of IL-10 in immunity and cancer, Cancer Lett., 367, 103, 10.1016/j.canlet.2015.07.009 · DOI · Paper page
  84. Salgado, 2003, Circulating interleukin-6 predicts survival in patients with metastatic breast cancer, Int. J. Cancer, 103, 642, 10.1002/ijc.10833 · DOI · Paper page
  85. Lu, 2017, Impact of IL-12 in Cancer, Curr. Cancer Drug Targets, 17, 682, 10.2174/1568009617666170427102729 · DOI
  86. Setrerrahmane, 2017, Tumor-related interleukins: Old validated targets for new anti-cancer drug development, Mol. Cancer, 16, 153, 10.1186/s12943-017-0721-9 · DOI · Paper page
  87. Choudhry, 2018, Prospects of IL-2 in Cancer Immunotherapy, Biomed Res. Int., 2018, 9056173, 10.1155/2018/9056173 · DOI
  88. Martin, 2016, Targeting microenvironment in cancer therapeutics, Oncotarget, 7, 52575, 10.18632/oncotarget.9824 · DOI
  89. Hao, Y., Baker, D., and Ten Dijke, P. (2019). TGF-beta-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. Int. J. Mol. Sci., 20. · DOI · Paper page
  90. Liu, 2018, TGF-β signaling: A complex role in tumorigenesis (Review), Mol. Med. Rep., 17, 699
  91. Montfort, 2019, The TNF Paradox in Cancer Progression and Immunotherapy, Front. Immunol., 10, 1818, 10.3389/fimmu.2019.01818 · DOI · Paper page
  92. Ion, G.N.D., Nitulescu, G.M., and Popescu, C.I. (2019). Targeting TRAIL. Bioorg Med. Chem. Lett. · DOI
  93. Ikeda, 2002, The roles of IFN gamma in protection against tumor development and cancer immunoediting, Cytokine Growth Factor Rev., 13, 95, 10.1016/S1359-6101(01)00038-7 · DOI · Paper page
  94. Chow, 2014, Chemokines in cancer, Cancer Immunol. Res., 2, 1125, 10.1158/2326-6066.CIR-14-0160 · DOI · Paper page
  95. Salcedo, 2000, Human endothelial cells express CCR2 and respond to MCP-1: Direct role of MCP-1 in angiogenesis and tumor progression, Blood, 96, 34, 10.1182/blood.V96.1.34 · DOI · Paper page
  96. Payne, 2002, The role of chemokines in melanoma tumor growth and metastasis, J. Investig. Dermatol., 118, 915, 10.1046/j.1523-1747.2002.01725.x · DOI · Paper page
  97. Zheng, 2016, Recent advances in SCF ubiquitin ligase complex: Clinical implications, Biochim. Biophys. Acta, 1866, 12
  98. Carmeliet, 2005, VEGF as a key mediator of angiogenesis in cancer, Oncology, 69, 4, 10.1159/000088478 · DOI · Paper page
  99. Zeng, 2014, Epidermal growth factor, from gene organization to bedside, Semin. Cell Dev. Biol., 28, 2, 10.1016/j.semcdb.2014.01.011 · DOI · Paper page
  100. Jutten, 2014, EGFR signaling and autophagy dependence for growth, survival, and therapy resistance, Cell Cycle, 13, 42, 10.4161/cc.27518 · DOI
  101. Newell, 2017, Placental growth factor: What hematologists need to know, Blood Rev., 31, 57, 10.1016/j.blre.2016.08.004 · DOI
  102. Heldin, 2013, Targeting the PDGF signaling pathway in tumor treatment, Cell Commun. Signal., 11, 97, 10.1186/1478-811X-11-97 · DOI · Paper page
  103. Vella, V., Malaguarnera, R., Nicolosi, M.L., Morrione, A., and Belfiore, A. (2019). Insulin/IGF signaling and discoidin domain receptors: An emerging functional connection. Biochim. Biophys. Acta Mol. Cell Res., 118522. · DOI
  104. Sarkar, 2016, Dynamic analysis of immune and cancer cell interactions at single cell level in microfluidic droplets, Biomicrofluidics, 10, 054115, 10.1063/1.4964716 · doi:10.1063/1.4964716
  105. Yuan, 2019, Systematic expression analysis of ligand-receptor pairs reveals important cell-to-cell interactions inside glioma, Cell Commun. Signal., 17, 48, 10.1186/s12964-019-0363-1 · DOI
  106. Lucchetti, D., Ricciardi Tenore, C., Colella, F., and Sgambato, A. (2020). Extracellular Vesicles and Cancer: A Focus on Metabolism, Cytokines, and Immunity. Cancers (Basel), 12. · DOI
  107. Santi, 2015, Cancer associated fibroblasts transfer lipids and proteins to cancer cells through cargo vesicles supporting tumor growth, Biochim. Biophys. Acta, 1853, 3211, 10.1016/j.bbamcr.2015.09.013 · DOI
  108. Curtis, 2019, Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis, Cell Metab., 29, 141, 10.1016/j.cmet.2018.08.007 · DOI · Paper page
  109. Vasseur, 2016, Lipid metabolic reprogramming in cancer cells, Oncogenesis, 5, e189, 10.1038/oncsis.2015.49 · DOI · Paper page
  110. Shender, 2014, Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication, Mol. Cell. Proteom., 13, 3558, 10.1074/mcp.M114.041194 · DOI
  111. Nieman, 2011, Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth, Nat. Med., 17, 1498, 10.1038/nm.2492 · DOI · Paper page
  112. Tang, 2016, Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC), Oncotarget, 7, 46253, 10.18632/oncotarget.10086 · DOI
  113. Wang, 2010, Eicosanoids and cancer, Nat. Rev. Cancer, 10, 181, 10.1038/nrc2809 · DOI · Paper page
  114. Chang, 2004, Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression, Proc. Natl. Acad. Sci. USA, 101, 591, 10.1073/pnas.2535911100 · DOI · Paper page
  115. Buchanan, 2003, Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor, J. Biol. Chem., 278, 35451, 10.1074/jbc.M302474200 · DOI · Paper page
  116. Xiang, 2009, Induction of myeloid-derived suppressor cells by tumor exosomes, Int. J. Cancer, 124, 2621, 10.1002/ijc.24249 · DOI · Paper page
  117. Heusinkveld, 2011, M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells, J. Immunol., 187, 1157, 10.4049/jimmunol.1100889 · DOI · Paper page
  118. Chen, 2014, Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression, Breast Cancer Res., 16, 410, 10.1186/s13058-014-0410-1 · DOI
  119. Wculek, 2015, Neutrophils support lung colonization of metastasis-initiating breast cancer cells, Nature, 528, 413, 10.1038/nature16140 · DOI · Paper page
  120. Kuwata, 2013, Extracellular lipid metabolism influences the survival of ovarian cancer cells, Biochem. Biophys. Res. Commun., 439, 280, 10.1016/j.bbrc.2013.08.041 · doi:10.1016/j.bbrc.2013.08.041
  121. Visentin, 2006, Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages, Cancer Cell, 9, 225, 10.1016/j.ccr.2006.02.023 · DOI · Paper page
  122. Anelli, 2010, Role of sphingosine kinase-1 in paracrine/transcellular angiogenesis and lymphangiogenesis in vitro, FASEB J., 24, 2727, 10.1096/fj.09-150540 · DOI
  123. Kanaporis, 2011, Gap junction permeability: Selectivity for anionic and cationic probes, Am. J. Physiol. Cell Physiol., 300, C600, 10.1152/ajpcell.00316.2010 · doi:10.1152/ajpcell.00316.2010
  124. Wu, 2019, Emerging roles of gap junction proteins connexins in cancer metastasis, chemoresistance and clinical application, J. Biomed. Sci., 26, 8, 10.1186/s12929-019-0497-x · DOI
  125. Tang, 2011, Expression and significance of Cx43 and E-cadherin in gastric cancer and metastatic lymph nodes, Med. Oncol., 28, 502, 10.1007/s12032-010-9492-5 · doi:10.1007/s12032-010-9492-5
  126. Alaga, 2017, Aberrant Cx43 Expression and Mislocalization in Metastatic Human Melanomas, J. Cancer, 8, 1123, 10.7150/jca.18569 · DOI
  127. Jensen, 2011, Inhibition of gap junction transfer sensitizes thyroid cancer cells to anoikis, Endocr. Relat. Cancer, 18, 613, 10.1530/ERC-10-0289 · DOI
  128. Kong, 2016, All-trans retinoic acid enhances bystander effect of suicide gene therapy in the treatment of breast cancer, Oncol. Rep., 35, 1868, 10.3892/or.2015.4535 · DOI
  129. Heiniger, 2010, Second-generation substituted quinolines as anticancer drugs for breast cancer, Anticancer Res., 30, 3927
  130. Wang, 2018, The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability, Cancer Cell, 34, 823, 10.1016/j.ccell.2018.10.002 · DOI
  131. Yang, 2018, Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression, Cancer Res., 78, 3761, 10.1158/0008-5472.CAN-18-0040 · DOI
  132. Dang, 2016, Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer, Expert Rev. Anticancer Ther., 16, 13, 10.1586/14737140.2016.1123626 · DOI
  133. Sundar, 2015, Nivolumab in NSCLC: Latest evidence and clinical potential, Ther. Adv. Med. Oncol., 7, 85, 10.1177/1758834014567470 · DOI · Paper page
  134. Philips, 2015, Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies, Int. Immunol., 27, 39, 10.1093/intimm/dxu095 · DOI · Paper page
  135. Wang, 2016, A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer, Medicine (Baltimore), 95, e5539, 10.1097/MD.0000000000005539 · DOI
  136. Besse, 2013, Phase Ib safety and pharmacokinetic study of volociximab, an anti-alpha5beta1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer, Ann. Oncol., 24, 90, 10.1093/annonc/mds281 · DOI
  137. Sarkari, 2019, Abstract 5156: In vitro application of tumor-treating fields to suppress tunneling nanotubes in mesothelioma, Cancer Res., 79, 5156, 10.1158/1538-7445.AM2019-5156 · doi:10.1158/1538-7445.am2019-5156
  138. Sarkari, 2019, Tumor-Treating Fields (TTFields) Suppress Tunneling Nanotube Formation in Malignant Mesothelioma, Int. J. Radiat. Oncol. Biol. Phys., 105, E662, 10.1016/j.ijrobp.2019.06.1058 · DOI
  139. Desir, S., O’Hare, P., Vogel, R., Sperduto, W., Sarkari, A., Dickson, E., Wong, P., Nelson, A., Fong, Y., and Steer, C. (2018). Chemotherapy-Induced Tunneling Nanotubes Mediate Intercellular Drug Efflux in Pancreatic Cancer. Sci. Rep., 8. · DOI
  140. Desir, 2016, Tunneling nanotube formation is stimulated by hypoxia in ovarian cancer cells, Oncotarget, 7, 43150, 10.18632/oncotarget.9504 · DOI
  141. Weil, 2017, Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas, Neuro Oncol., 19, 1316, 10.1093/neuonc/nox070 · DOI · Paper page
  142. Haderk, 2017, Tumor-derived exosomes modulate PD-L1 expression in monocytes, Sci. Immunol., 2, eaah5509, 10.1126/sciimmunol.aah5509 · DOI · Paper page
  143. Tian, 2019, Potential Role of Exosomes in Cancer Metastasis, Biomed Res. Int., 2019, 4649705, 10.1155/2019/4649705 · DOI
  144. Dong, 2012, Differential expression of Rab27A/B correlates with clinical outcome in hepatocellular carcinoma, World J. Gastroenterol., 18, 1806, 10.3748/wjg.v18.i15.1806 · DOI
  145. Richards, 2017, Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells, Oncogene, 36, 1770, 10.1038/onc.2016.353 · DOI · Paper page
  146. Marleau, 2012, Exosome removal as a therapeutic adjuvant in cancer, J. Transl. Med., 10, 134, 10.1186/1479-5876-10-134 · DOI · Paper page
  147. Tai, 2018, Exosomes in cancer development and clinical applications, Cancer Sci., 109, 2364, 10.1111/cas.13697 · DOI · Paper page
  148. Iero, 2008, Tumour-released exosomes and their implications in cancer immunity, Cell Death Differ., 15, 80, 10.1038/sj.cdd.4402237 · DOI · Paper page
  149. Rahbarghazi, 2019, Tumor-derived extracellular vesicles: Reliable tools for Cancer diagnosis and clinical applications, Cell Commun. Signal., 17, 73, 10.1186/s12964-019-0390-y · DOI · Paper page
  150. Tian, 2014, A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy, Biomaterials, 35, 2383, 10.1016/j.biomaterials.2013.11.083 · DOI · Paper page
  151. Rodon, 2015, First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma, Clin. Cancer Res., 21, 553, 10.1158/1078-0432.CCR-14-1380 · DOI · Paper page
  152. Kelley, 2019, A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma, Clin. Transl. Gastroenterol., 10, e00056, 10.14309/ctg.0000000000000056 · DOI · Paper page
  153. Herbertz, 2015, Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway, Drug Des. Dev. Ther., 9, 4479
  154. Fuji, 2018, Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: Clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation, Haematologica, 103, e211, 10.3324/haematol.2017.184564 · doi:10.3324/haematol.2017.184564
  155. Allison, 2017, Kidney cancer: CCR4: A new target for RCC, Nat. Rev. Nephrol., 13, 192, 10.1038/nrneph.2017.14 · doi:10.1038/nrneph.2017.14
  156. Massara, 2019, Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy, Front. Immunol., 10, 379, 10.3389/fimmu.2019.00379 · DOI · Paper page
  157. Shinriki, 2011, Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma, J. Pathol., 225, 142, 10.1002/path.2935 · DOI
  158. Jeannot, 2016, Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma, Onco Targets Ther., 9, 6843, 10.2147/OTT.S117743 · DOI
  159. Rock, 2007, Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma, Oncologist, 12, 107, 10.1634/theoncologist.12-1-107 · DOI · Paper page
  160. Chau, 2013, Vandetanib for the Treatment of Medullary Thyroid Cancer, Clin. Cancer Res., 19, 524, 10.1158/1078-0432.CCR-12-2353 · DOI
  161. Raouf, 2019, Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: A systematic literature review, Future Oncol., 15, 543, 10.2217/fon-2018-0480 · DOI
  162. Gardner, V., Madu, C., and Lu, Y. (2017). Anti-VEGF Therapy in Cancer: A Double-Edged Sword. Physiologic and Pathologic Angiogenesis. Signaling Mechanisms and Targeted Therapy, InTechOpen. · DOI
  163. Fuchs, 2014, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial, Lancet, 383, 31, 10.1016/S0140-6736(13)61719-5 · DOI · Paper page
  164. Pardee, 2014, A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies, Clin. Cancer Res., 20, 5255, 10.1158/1078-0432.CCR-14-1019 · DOI
  165. Lycan, T.W., Pardee, T.S., Petty, W.J., Bonomi, M., Alistar, A., Lamar, Z.S., Isom, S., Chan, M.D., Miller, A.A., and Ruiz, J. (2016). A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PLoS ONE, 11. · DOI
  166. Kamisuki, 2009, A small molecule that blocks fat synthesis by inhibiting the activation of SREBP, Chem. Biol., 16, 882, 10.1016/j.chembiol.2009.07.007 · DOI · Paper page
  167. Stepulak, 2015, Comprehensive review on betulin as a potent anticancer agent, Biomed Res. Int., 2015, 584189
  168. Siqingaowa, 2017, Sterol regulatory element-binding protein 1 inhibitors decrease pancreatic cancer cell viability and proliferation, Biochem. Biophys. Res. Commun., 488, 136, 10.1016/j.bbrc.2017.05.023 · DOI
  169. Cheng, 2018, SCAP/SREBPs are Central Players in Lipid Metabolism and Novel Metabolic Targets in Cancer Therapy, Curr. Top. Med. Chem., 18, 484, 10.2174/1568026618666180523104541 · DOI
  170. Koundouros, 2020, Reprogramming of fatty acid metabolism in cancer, Br. J. Cancer, 122, 4, 10.1038/s41416-019-0650-z · DOI · Paper page
  171. Dean, 2016, Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, J. Clin. Oncol., 34, 2512, 10.1200/JCO.2016.34.15_suppl.2512 · DOI
  172. Kock, 2018, Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth, EBioMedicine, 32, 84, 10.1016/j.ebiom.2018.05.008 · DOI
  173. Britten, 2017, A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors, Clin. Cancer Res., 23, 4642, 10.1158/1078-0432.CCR-16-2363 · DOI · Paper page
  174. Eugenin, E. (2019). Role of cell-to-cell communication in cancer: New features, insights, and directions. Cancer Rep. · DOI

Cited by

See all 188

Metadata

Authors
Dominiak, A., Chełstowska, B., Olejarz, W., & Nowicka, G.
Affiliations
  • Department of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland
  • Department of Internal Medicine and Hematology, Laboratory of Hematology and Flow Cytometry, Military Institute of Medicine, 04-140 Warsaw, Poland
Venue
Cancers
Publisher
MDPI AG
Published
2020-05-14
Volume
12
Issue
5
Pages
1232
ISSN
2072-6694
Cited by
188
References
16
Language
en
Funders
Medical University of Warsaw (Profile of selected factors secreted by fibroblasts at various cancer stages)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions. https://app.cochat.ai/papers/10.3390/cancers12051232
The paper
Dominiak, A., Chełstowska, B., Olejarz, W., & Nowicka, G. (2020). Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions. Cancers. https://doi.org/10.3390/cancers12051232

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.